997 LENOX DRIVE, LAWRENCEVILLE, NJ
Reports Second Quarter 2026 Financial Results and Provides Business Update
Compensatory Programs Approved for Executive Officers at Imunon, Inc.
Changes in Board, Management or Compensation
Stockholders Approve Amendment to 2018 Stock Incentive Plan
Announces Up to $10 Million Cash Financing
Reports First Quarter 2026 Financial Results and Provides Business Update
Change of Control Agreements for Executives at Imunon, Inc.
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence